EGFR and non-small cell lung carcinoma: AZD9291 (osimertinib) is an oral third‐generation EGFR‐TKI and the first drug to target EGFR gene mutations (including mutations at residues 18, 19, and 21) and EGFR‐TKI acquired resistance (T790M) in NSCLC.248